Stipple Bio, Inc.

Stipple Bio, Inc. is a US-based biotechnology company that focuses on developing precision medicines for oncology, utilizing innovative techniques to identify and map tumor-specific epitopes in order to enhance cancer treatment options. Founded in 2022 and headquartered in Cambridge, US, Stipple Bio, Inc. specializes in the research and development of targeted cancer therapies.

The company has completed three funding deals to date, including a Series A round in March 2026, which raised USD 65. 13 mn from investors such as Andreessen Horowitz and RA Capital Management. The company was founded by individuals with a background in biotechnology and cancer research, although specific details on the founder's previous ventures are not available. Stipple Bio is focused on revolutionizing targeted oncology through the development of precision medicines aimed at treating cancer.

Their core offerings center around the identification and mapping of tumor-specific epitopes, utilizing a unique approach that emphasizes the detection of subtle molecular points—termed "dots"—to create a comprehensive therapeutic picture. This methodology allows Stipple Bio to systematically differentiate between established, emerging, and novel tumor targets that conventional antibody discovery methods often overlook. The end users of these products include healthcare providers and research institutions, primarily in North America and Europe, who are seeking advanced options for targeted cancer therapies. By leveraging their precision-driven technology, Stipple Bio aims to provide innovative solutions for patients suffering from various forms of cancer.

Stipple Bio’s revenue model is primarily structured around partnerships with healthcare providers, research institutions, and potentially pharmaceutical companies, enabling the commercialization of their innovative cancer therapies. Transactions are carried out through collaborations and licensing agreements, allowing clients to integrate Stipple Bio's proprietary technologies into their own research and treatment protocols. Typical transaction structures may involve collaborative research agreements, where Stipple Bio partners with biotech firms or academic institutions to develop targeted therapies, as well as direct sales of their proprietary technologies. While specific pricing plans for their offerings have not been disclosed, the revenue from their flagship products is supported through substantial partnerships in the oncology sector.

In March 2026, Stipple Bio, Inc. raised USD 65. 13 mn in Series A funding co-led by RA Capital Management, Nextech, and Andreessen Horowitz. The company plans to use this funding to advance its lead candidate, STP-100, into multiple early-stage clinical studies starting in early 2027 and to support operations through 2029.

Stipple Bio is focused on launching new products and expanding its market reach, particularly in North America and Europe, to enhance its offerings in targeted oncology.